Abstract: The present invention is in the field of hair treatment compositions; in particular relates to a method for hair volume reduction. Despite the prior art, there still exists the opportunity to increase the conditioning benefits delivered through hair treatment compositions. It is therefore an object of the present invention to provide a method that retains shape and reduces frizz even after exposure to humidity and washing the hair. It has been found that reduced hair frizz and hair shape retention even after exposure to moisture can be obtained by using N-formyl amino acids.

Abstract: A contact lens or conjunctival cover, including an internal absorbent medium; an external carrier medium; the external carrier medium having openings therein that allow fluid to pass between an exterior of the contact lens or conjunctival cover and the internal absorbent medium thereby to be absorbed and released by the internal absorbent medium. Also, a method of treating dry eye syndrome, including: gathering donor tears from eyes of an individual having healthy tears; storing the donor tears in an absorbent medium; placing the absorbent medium with the donor tears absorbed therein in contact with an eye or eyes affected by dry eye syndrome; and dispersing the donor tears over an ocular surface of the eyes affected by dry eye syndrome.

Abstract: The present invention provides an emulsified gel composition comprising a physiologically active substance, water, a gelling agent, an anti-peeling agent, and a surfactant having an HLB value of 18 to 20, in which the gelling agent is a nonionic water-soluble polymer, and the anti-peeling agent is one or more compounds selected from the group consisting of sucrose, sorbitol, polyethylene glycol, glycerin, a (meth)acrylic-based polymer compound, and a polyoxyethylene hydrogenated castor oil.

Abstract: The invention relates to a false nail comprising at least: one front layer (12) forming the body of the false nail (1), and a rear layer (11) of an adhesive material for attaching the body of the false nail to a natural nail. The rear layer (11) is formed by a fast-drying polymer adhesive with desiccating capacity, and the front layer (12) is made of a composite material and comprises at least a first layer (12a) of micro-hybrid composite with low contraction capacity in contact with the polymer adhesive. The invention also relates to a method for shaping the false nail on a natural nail and the use of composite material to shape same.

Abstract: The invention relates to medicines, and more particularly to an abortion medication and an administration thereof, where the abortion medication contains 40-60 mg/mL of a kidney bean lectin. The invention also provides another abortion medication, which contains 40-60 mg/mL of a kidney bean lectin, 40-50 mg/mL of an oligosaccharide and 6-9 mg/mL of NaCl. The two abortion medications provided herein are both capable of effectively terminating the pregnancy and are safe without toxic side effects. Moreover, these drugs can be reused several times. These abortion medications are administered intrauterinely, which enables the kidney bean lectin therein to show the best abortive effect, and the local administration of these drugs in the uterine cavity has relatively simple operation.

Abstract: A method of making an oral soluble film, containing at least one active agent, includes providing a well of a predetermined size; depositing a film forming composition in the well; depositing an active agent composition in the well, the active agent composition being different than the film forming composition, the film forming composition and the active agent composition forming an admixture in the well; and drying the admixture in the well. Alternatively, the method includes providing a well of a predetermined size; depositing a film forming composition including at least one active agent in the well, the film forming composition having a viscosity below 2000 centipoise; and drying the film forming composition in the well.

Abstract: The present invention relates to a composition for controlling plant diseases containing a limonene derivative as an active ingredient. In the present invention, the limonene derivatives have an effect of inhibiting the growth of Xanthomonas oryzae pv. Oryzae (Xoo), which is a pathogen mediating bacterial leaf blight, and Magnaporthe oryzae, which is a pathogen mediating rice blast, and it was confirmed in an experiment with respect to inhibition using volatility (i.e., in a state not being in direct contact with Xoo or M. oryzae) that the limonene derivatives have a growth inhibitory effect. Accordingly, the limonene derivatives have an inhibitory effect against the growth of Xoo and thus they can be effectively used as a composition for controlling plant diseases.

Abstract: A combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin, and a medical product or pharmaceutical composition comprising such combination, useful for the treatment of a variety of diseases and conditions is described. The combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin is also useful for cosmetic treatment of skin and as an antibacterial agent.

Abstract: To provide a phosphatidylcholine transdermal absorption preparation containing phosphatidylcholine in an adhesive layer. A phosphatidylcholine transdermal absorption preparation has a configuration in which an adhesive layer formed on at least one side of a support contains phosphatidylcholine, an adhesive component, and a lipophilic component, and thus the preparation becomes a patch-type transdermal absorption preparation which acts as a fat-decreasing agent which contains phosphatidylcholine and can exert an effect that local obesity such as subcutaneous fat is dissolved and fat is decreased by transdermal absorption of phosphatidylcholine as the preparation is pasted to the skin of a human body since phosphatidylcholine can be stably present in the adhesive layer and has an advantage due to the patch dosage form that the preparation can be fixed to the affected area and is more favorably handled as compared to liquid preparations and the like.

Abstract: A pharmaceutical composition in a form of dry powder for intranasal administration includes solid particles of at least one opioid receptor antagonist as active ingredient and two types of solid particles. A naloxone pharmaceutical composition in the form of dry powder for intranasal administration, including as active agent naloxone or a pharmaceutically acceptable salt thereof. A kit for intranasal administration of naloxone. A method of treating opioid overdose/intoxication and/or a symptom thereof in a patient in need thereof by intranasally administering a therapeutically effective amount of a composition including solid particles of at least one opioid receptor antagonist as active ingredient and two types of solid particles.

Abstract: Pharmaceutical compositions of one or more opioid antagonists or phosphodiesterase 5 (PDE5) inhibitors are disclosed.

Abstract: A solid anhydrous composition for caring for and/or making up keratin materials comprising: a) at least one triglyceride oil according to formula (I): CH2(OOCR1)CH(OOCR2)CH2(OOCR3) (I) wherein R1, R2 and R3 are independently chosen from C6-C30 alkyl and C6-C30alkenyl; b) at least one triglyceride oil according to formula (II): CH2(OOCR1)CH(OOCR2)CH2(OOCR3) (II) wherein R1, R2 and R3 are independently chosen from C6-C30 alkyl and C6-C30alkenyl, at least one of R1, R2 and R3 is substituted with a hydroxyl; c) at least one pasty compound chosen from an ester of dimer dilinoleic acid and polyol(s) or an ester thereof, and d) at least one wax, wherein the triglyceride oil according to formula (I) and the triglyceride oil according to formula (II) are present in the solid anhydrous composition in a weight ratio less than or equal to 1:1.

Abstract: The present invention relates to balloon catheters with or without crimped stent, whose surface is coated with at least one antirestenotic agent and at least one transport promoting molecular dispersant, as well as a method for the preparation of these medical devices.

Abstract: The present invention provides an oral transmucosal film or patch for delivering doxepin through the buccal mucosa or sublingual mucosa. The film or patch is a bilayer structure containing a mucoadhesive layer with amorphous doxepin and soluble backing layer without doxepin. The film or patch has satisfactory bioavailability and improved palatability. The mucoadhesive layer comprises 0.5-25% (w/w) of doxepin, 50-96% of one or more film-forming agents, 1-30% (w/w) of one or more adhesives, and 0.05-5% (w/v) of one or more stabilizers. The backing layer comprises 80-100% (w/w) of one or more film-forming agents. Preferred adhesives include povidone, carbomer, and polycarbophil. Preferred stabilizers include butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), citric acid, and ascorbic acid.

Abstract: An oral soluble film contains at least one active agent. Alternatively, a multi-layered film includes a plurality of layers, at least one at least one of the plurality of layers being an oral soluble film layer containing at least one active agent. The oral soluble film may be made, e.g., by a method comprising providing a well of a predetermined size; depositing a film forming composition in the well; metering a predetermined amount of an active agent composition in the well separately from the film forming composition, the active agent composition being different than the film forming composition, the film forming composition and the active agent composition forming a single layer in the well; and drying the single layer in the well to form the oral soluble film containing the at least one active agent.

Abstract: Disclosed herein are compositions and methods for treating lung disorders including lung tumors by pulmonary administration of compositions comprising taxane particles such as docetaxel or paclitaxel particles.

Abstract: The present invention is about composition for preventing hair loss or promoting hair growth comprising indirubin derivatives; and one or more selected from the group consisting of Euodia daniellii extract, Persicaria hydropiper extract, Hovenia dulcis extract, methyl vanillate, hesperidin and quercitrin; as an active ingredient. In addition, one or more selected from the group consisting of Euodia daniellii extract, Persicaria hydropiper extract, Hovenia dulcis extract, methyl vanillate, hesperidin and quercitrin of the present invention is a natural-derived composition with little toxicity to cells. Indirubin derivatives are stable compounds that have been found to have little toxicity to the human body, and therefore, when used in a mixture thereof, there are advantages in that they do not exhibit adverse effects on the human body, unlike conventional steroid drugs.

Abstract: A scaffold of hollow fibers comprising a mixture of polylactic acid (PLA) and polybutylene succinate (PBS) and cellulose nanofibers (CNF), medical products made of these scaffolds and methods of using the scaffolds in regenerative medicine. A method for producing the scaffolds is also disclosed.

Abstract: The present invention provides a liquid composition comprising a pharmaceutically active compound and an aqueous polymer dispersion, wherein said liquid composition forms a film upon drying under standard ambient temperature and pressure; a method for providing the same; and a container comprising said liquid composition.

Abstract: A scaffold of hollow fibers comprising a mixture of polylactic acid (PLA) and polybutylene succinate (PBS) and cellulose nanofibers (CNF), medical products made of these scaffolds and methods of using the scaffolds in regenerative medicine. A method for producing the scaffolds is also disclosed.